Öztürk Ateş

Absolute Survival Benefit of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer: A Reconstructed Individual Patient Data Re-analysis of RASolute 302

Osman Bilge Kaya, Berkan Karabuğa, Ergin Aydemir, Elif Sertesen et autres

Code and data for a restricted mean survival time (RMST) re-analysis of the RASolute 302 trial (daraxonrasib versus investigator's choice chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma; ClinicalTrials.gov NCT06625320), based on individual patient data reconstructed from the published Kaplan-Meier curves (O'Reilly …

tr (code pays fourni par la source)

Absolute Survival Benefit of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer: A Reconstructed Individual Patient Data Re-analysis of RASolute 302

Osman Bilge Kaya, Berkan Karabuğa, Ergin Aydemir, Elif Sertesen et autres

Code and data for a restricted mean survival time (RMST) re-analysis of the RASolute 302 trial (daraxonrasib versus investigator's choice chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma; ClinicalTrials.gov NCT06625320), based on individual patient data reconstructed from the published Kaplan-Meier curves (O'Reilly …

tr (code pays fourni par la source)

Analysis code for "Mucosal, ocular and pulmonary adverse events reported with datopotamab deruxtecan: an indication-restricted disproportionality analysis of the FDA Adverse Event Reporting"

Osman Bilge Kaya, Berkan Karabuğa, Ergin Aydemir, Mehmet Emin Yılmaz et autres

tr (code pays fourni par la source)

Analysis code for "Mucosal, ocular and pulmonary adverse events reported with datopotamab deruxtecan: an indication-restricted disproportionality analysis of the FDA Adverse Event Reporting"

Osman Bilge Kaya, Berkan Karabuğa, Ergin Aydemir, Mehmet Emin Yılmaz et autres

tr (code pays fourni par la source)

Comparison of Direct Oral Anticoagulants and Low-Molecular-Weight Heparins in Cancer Patients with Nonvalvular Atrial Fibrillation: Insights from a Single-Center Experience

İmran Ceren, Y Z Sener, Kemal Göçer, Hatice Gülgün Fırat et autres

BACKGROUND: Atrial fibrillation (AF) is frequently encountered in patients with cancer and poses challenges for anticoagulant management. The present study was conducted to compare clinical outcomes associated with direct oral anticoagulants (DOACs) and low-molecular-weight heparin (LMWH) in individuals with active malignancy and …

tr, nl (code pays fourni par la source)

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

Fatih Kuş, Fatih Atalah, Gökhan Şahin, Caner Kapar et autres

Abstract Background Thymic carcinoma (TC) is a rare and aggressive malignancy with limited evidence guiding second-line treatment after prior systemic therapy. We evaluated real-world outcomes of second-line systemic therapy in a multicenter cohort. Methods Adults with unresectable, recurrent, or metastatic TC who …

tr (code pays fourni par la source)

Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

Pınar Kubilay Tolunay, Bediz Kurt İnci, Berkan Karabuğa, Ali Topkaç et autres

Background/Objectives: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are commonly used as first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. However, the optimal timing of CDK4/6i initiation remains uncertain. This study compared overall survival (OS) between upfront …

tr (code pays fourni par la source)

Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2−metastatic breast cancer

Tuğba Önder, Öztürk Ateş

tr (code pays fourni par la source)

Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study

Tuğba Önder, Öztürk Ateş

tr (code pays fourni par la source)

Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

Cihan Erol, Esra Zeynelgil, Mutlu Hızal, Aysegul Dumludag et autres

tr, us (code pays fourni par la source)

From the stands to survival fandom, a psychosocial force in the fight against cancer

Berkan Karabuğa, Ekin Konca Karabuğa, Ergin Aydemir, Osman Bilge Kaya et autres

This study investigated the association between sports fandom, hope, and treatment adherence in patients with cancer. A total of 306 patients with solid tumors receiving chemotherapy or immunotherapy completed the State Hope Scale, Patient Adherence Scale, and questionnaires assessing team support and …

tr (code pays fourni par la source)

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

Bahadır Köylü, Ozde Melisa Celayir, Harun Muğlu, Orcun Can et autres

Background/Objectives: We aimed to evaluate the real-world outcomes of first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer, together with the progression patterns, including the management and outcomes of oligoprogressive disease in the real-world setting. Methods: Patients who received first-line …

tr (code pays fourni par la source)